December 16, 2022 –
Ferring Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approved Adstiladrin ® (nadofaragene firadenovec-vncg)
December 13, 2022 –
Idacio (adalimumab-aacf), a tumor necrosis factor (TNF) blocker biosimilar to Humira, has been approved by the FDA for the treatment of rheumatoid arthritis